The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates

Journal of Pharmacology and Experimental Therapeutics

Volumn 312, Issue 3, 2005, Pages 1144-1150

  Vitseva, Olga ^a   Flockhart, David A ^b   Jin, Yan ^b   Varghese, Sonia ^a   Freedman, Jane E ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNORTAMOXIFEN; 4 HYDROXYTAMOXIFEN; CYCLIC GMP; DRUG METABOLITE; ESTRADIOL; NITRIC OXIDE; NORTAMOXIFEN; PROTEIN P47; PROTEIN P67; PROTEIN SUBUNIT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

BLOOD PLATELETS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MALE; NADPH OXIDASE; NITRIC OXIDE; PHOSPHOPROTEINS; PLATELET AGGREGATION; REACTIVE OXYGEN SPECIES; TAMOXIFEN;

EID: 14344251109     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.076315     Document Type: Article

References (34)

1. Chang J, Powles TJ, Ashley SE, Gregory RK, Tidy VA, Treleaven JG, and Singh R (1996) The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 7:671-675.
2. Clutton P, Miermont A, and Freedman JE (2004) Regulation of endogenous reactive oxygen species in platelets can reverse aggregation. Arterioscler Thromb Vasc Biol 24:187-192.
3. Crewe HK, Ellis SW, Lennard MS, and Tucker GT (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53:171-178.
4. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J Am Med Assoc 281:2189-2197.
5. Decensi A, Gandini S, Guerrieri-Gonzaga A, Johansson H, Manetti L, Bonanni B, Sandri MT, Barreca A, Costa A, Robertson C, et al. (1999) Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 17:2633-2638.
6. de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, and Sixma JJ (1992) Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 85:2284-2290.
7. Duggan C, Marriott K, Edwards R, and Cuzick J (2003) Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 21:3588-3593.
8. Freedman J and Keaney J (1999) NO and superoxide in human platelets, in Methods in Enzymology: Nitric Oxide, Part C: Biological and Antioxidant Activities (Packer L ed) pp 61-67, Academic Press, San Diego.
9. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF Jr, and Michelson A (1997) Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Investig 100:350-356.
10. Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, and Michelson AD (1996) Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Investig 97:979-987.
11. Furr BJ and Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205.
12. Gundimeda U, Chen ZH, and Gopalakrishna R (1996) Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem 271:13504-13514.
13. Handin R, Karabin R, and Boxer G (1987) Enhancement of platelet aggregation by superoxide anion. J Clin Investig 59:959-965.
14. Jayachandran M and Miller VM (2003) Human platelets contain estrogen receptor alpha, caveolin-1 and estrogen receptor associated proteins. Platelets 14:75-81.
15. Jordan V, Collins M, Rowsby L, and Prestwich G (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305-316.
16. Khetawat G, Faraday N, Nealen ML, Vijayan KV, Bolton E, Noga SJ, and Bray PF (2000) Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood 95:2289-2296.
17. Krotz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM, Becker BF, Theisen K, Klauss V, and Pohl U (2002) NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 100:917-924.
18. Lee KH, Ward BA, Desta Z, Flockhart DA, and Jones DR (2003) Quantification of tamoxifen and three metabolites hi plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci 791:245-253.
19. Lee YS, Kang YS, Lee SH, and Kim JA (2000) Role of NAD(P)H oxidase in the tamoxifen-induced generation of reactive oxygen species and apoptosis in HepG2 human hepatoblastoma cells. Cell Death Differ 7:925-932.
20. Love RR, Surawicz TS, and Williams EC (1992) Antithrombin III level, fibrinogen level and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med 152:317-320.
21. Mandlekar S, Yu R, Tan TH, and Kong AN (2000) Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 60:5995-6000.
22. Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, and Veronesi U (1996) Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 156:1806-1810.
23. Marttunen MB, Pyrhonen S, Tiitinen AE, Viinikka LU, and Ylikorkala O (1996) Effect of antiestrogen regimen on prostacyclin and thromboxane A2 in postmenopausal patients with breast cancer: evidence of significance of hypertension, smoking or previous use of estrogen therapy. Prostaglandins 52:317-326.
24. Miller ME, Dores GM, Thorpe SL, and Akerley WL (1994) Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thromb Res 74:577-594.
25. Miller ME, Thorpe SL, and Dores GM (1995) Influence of hormones on platelet intracellular calcium. Thromb Res 77:515-530.
26. Nakano Y, Oshima T, Matsuura H, Kajiyama G, and Kambe M (1998) Effect of 17beta-estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis. Arterioscler Thromb Vasc Biol 18:961-967.
27. Nealen ML, Vijayan KV, Bolton E, and Bray PF (2001) Human platelets contain a glycosylated estrogen receptor beta. Circ Res 88:438-442.
28. Pagano G, de Biase A, Deeva IB, Degan P, Doronin YK, Iaccarino M, Oral R, Trieff NM, Warnau M, and Korkina LG (2001) The role of oxidative stress in developmental and reproductive toxicity of tamoxifen. Life Sci 68:1735-1749.
29. Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, and Pater J (1996) Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 14:2731-2737.
30. Santos MT, Valles J, Marcus AJ, Safier M, Broekman J, Islam N, Ullman HL, Eiroa AM, and Aznar J (1991) Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Investig 87:571-580.
31. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, and Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764.
32. Wagner AH, Schroeter MR, and Hecker M (2001) 17beta-Estradiol inhibition of NADPH oxidase expression in human endothelial cells. FASEB J 15:2121-2130.
33. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, and Anderson PW (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc 279:1445-1451.
34. Yue TL, Vickery-Clark L, Louden CS, Gu JL, Ma XL, Narayanan PK, Li X, Chen J, Storer B, Willette R, et al. (2000) Selective estrogen receptor modulator idoxifene inhibits smooth muscle cell proliferation, enhances reendothelialization and inhibits neointimal formation in vivo after vascular injury. Circulation 102:III281-III288.